An announcement from Akili (AKLI) is now available.
Akili, Inc. recently completed a significant corporate transaction when it was acquired by Virtual Therapeutics Corporation through a merger process. Shareholders of Akili saw their common stock purchased at $0.4340 per share in a tender offer that concluded on July 1, 2024, with the merger following the next day. This move resulted in Akili becoming a wholly-owned subsidiary of Virtual Therapeutics Corporation, and its common stock was subsequently delisted from Nasdaq. This strategic acquisition is a noteworthy event for market watchers and investors, as it potentially reshapes the competitive landscape within the industry.
See more insights into AKLI stock on TipRanks’ Stock Analysis page.
